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Summary
Introduction: Severe acute respiratory syndrome (SARS) is an emerging infectious
disease that first occurred in humans in the People’s Republic of China in November
2002 and has subsequently spread worldwide. A novel virus belonging to the
Coronaviridae family has been identified as the cause of this pulmonary disease.
The severity of the disease combined with its rapid spread requires the development
of fast and sensitive diagnostic assays.
Results: A real-time quantitative RT-PCR was designed in the nsp11 region of the
replicase 1B domain of the SARS-coronavirus (SARS-CoV) genome. To evaluate this
quantitative RT-PCR, cRNA standards were constructed by in vitro transcription of
SARS-CoV Frankfurt 1 RNA using T7 RNA polymerase, followed by real-time RT-PCR.
The assay allowed quantitation over a range of 102 to 108 RNA copies per reaction.
Conclusions: Extrapolated to clinical samples, this novel assay has a detection range
of 104 to 1010 copies of viral genome equivalents per millilitre. In comparison to the
current de facto cRNA Artus Biotech standard, the in-house cRNA standard gives a 100-
fold higher absolute quantity, suggesting a possible underestimation of the viral load
when using the Artus Biotech standard.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
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Severe acute respiratory syndrome (SARS) has
recently emerged as a new severe human disease
that resulted in 774 deaths and more than 8000
reported probable cases worldwide.1 The SARS epi-
demic began in the Guangdong province in southern
China, where several cases of atypical pneumonia of
unknown etiology were reported in November 2002.
A novel member of the Coronaviridae family has
been identified as the causative agent of this pul-
monary disease.2—6 The SARS-coronavirus (SARS-
CoV) is a new coronavirus type, of which the mor-
phology and genome organization are very similar to
those of other coronaviruses. Phylogenetic analyses
and sequence comparisons showed that SARS-CoV is
not closely related to any of the previously char-
acterized coronaviruses.6,7
The clinical case definition of SARS is essentially
one of fever and pneumonia, with or without a
contact history. In the absence of a definite history
of contact with other SARS patients, it is not easy to
differentiate SARS from other causes of atypical
pneumonia. Laboratory SARS-CoV confirmation tests
are therefore a critical clinical need. Detection of
specific SARS-CoVantibodies has been a reliable way
to confirm the diagnosis. Due to the fact that the
antibody response appears only around day ten of
the illness, IgM or other subtype assays have not
been useful for closing the diagnostic window within
the first week of illness.
Virus culture is relatively insensitive, and takes
too much time to be clinically relevant. During the
epidemic, a variety of reverse transcription-poly-
merase chain reaction (RT-PCR) assays were devel-
oped3,8 including a commercial ready-to-use RT-PCR
kit (Artus Biotech, Hamburg, Germany). Detection
of viral RNA by RT-PCR in clinical samples offers the
opportunity of diagnosis in an earlier stage of the
disease.9
In contrast to many other acute respiratory infec-
tions, viral loads in clinical samples are low in the
first few days of illness and peak around day ten of
the disease. Recently Ng and colleagues demon-
strated the role of serum SARS-CoV viral load mea-
surement as a prognostic marker, even on the first
day of hospital admission. A high systemic viral load
may directly lead to severe tissue damage, or indir-
ectly through the activation of a potentially dama-
ging immune reaction.10 For SARS-CoV diagnosis,
plasma or serum RT-PCR can be performedwith high
sensitivity during the first week of the disease.
Stool and respiratory samples can be used during
the second week, and serologic testing for antibo-
dies against SARS-CoV can be used from day 21
onward.11 A major advantage of real-time PCR isthat amplification and analysis are completed in a
closed system. The risk of contamination, which
can confound conventional (nested) RT-PCR proto-
cols, is markedly reduced. This paper presents a
very sensitive and specific quantitative RT-PCR
assay, which can contribute to a rapid and efficient
diagnosis of SARS in case of a new outbreak.Materials and methods
Viral propagation
The SARS-CoV Frankfurt 1 (FFM-1) strain was kindly
provided by Professor Dr H.F. Rabenau and Professor
Dr H.W. Doerr from the Johann Wolfgang Goethe
University, Frankfurt, Germany. SARS-CoV was pro-
pagated in African green monkey kidney cells (Vero
E6 cells), obtained from the American Type Culture
Collection (ATCC C1008). Supernatant was har-
vested after four days incubation at 37 8C in a 5%
CO2 atmosphere. Human coronaviruses OC43 and
229E were also obtained from the American Type
Culture Collection (VR-759 and VR-740). Viral RNA
was isolated using the QIAamp viral RNA kit (Qiagen,
Westburg, Leusden, The Netherlands).
Primer and probe design
The nsp11 region of the replicase 1B domain of the
SARS-CoV genome was screened for primer and
probe target sites that would be compatible with
TaqMan PCR requirements (ABI 7700 Users Manual),
using the Primer express 2.0 software. Primers span-
ning a target region of 68 bp were selected, with
matched dissociation temperatures and a minimal
likelihood for duplex or hairpin formation: forward
primer SARS-FP (50-CACCCGCGAAG-AAGCTATTC-30),
MGB probe SARS-TP (FAM 50-TGCGTGGATTGGCTT-
30NFQ-MGB), and reverse primer SARS-RP (50-TTGC-
ATGACAGCCCTCTACATC-30).
Construction of cRNA standards
The TaqMan SARS-CoV forward primer was modified
with a T7-promoter sequence at the 50-end (SARS-
FPT7 50-TAATACGACTCACTATAGGGAGGCACCCGCGA-
AGAAGCTA-TTC-30). PCR products amplified with the
modified primer pairs were quantified spectropho-
tometrically at 260 nm. Two hundred nanograms of
PCR product were used for in vitro transcription
(MEGAshortscript T7 kit, Ambion, Austin, TX, USA)
performed at 37 8C overnight in a 20 ml reaction mix
containing 2 ml of reaction buffer, 2 ml of each dNTP
and 2 ml enzyme mix. The cDNA was removed by
digestion with two units of RNase-free DNase I for
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ing 3 ml 3 M NaOAc and 60 ml of 96% ethanol and a
subsequent incubation at —20 8C for 30 min. After
centrifugation at 13000 rpm for 15 min, the super-
natant was removed and 500 ml 70% ethanol was
added. After another 5 min of centrifugation at
13000 rpm, the supernatant was removed and the
pellet was dissolved in 200 ml RNase free H2O
(Sigma-Aldrich NV, Bornem, Belgium) and stored
at —80 8C. Quantitation of cRNA was performed
spectrophotometrically at 260 nm.12
Real-time quantitative RT-PCR
A 25 ml RT-PCR was carried out using 5 ml of
extracted RNA or standard cRNA, 12.5 ml of a
real-time One-Step RT-PCR Master Mix containing
ROX as a passive reference (Applied Biosystems,
Foster City, CA, USA), 900 nM forward and reverse
primer, and 150 nM MGB probe. Amplification and
detection were performed in a ABI PRISM 7700
Sequence Detection System (Applied Biosystems,
Foster City, CA, USA) under the following conditions:
an initial reverse transcription at 48 8C for 30 min,
followed by PCR activation at 95 8C for 10 min and
45 cycles of amplification (15 seconds at 95 8C and
1 min at 60 8C). During amplification, the ABI PRISM
sequence detector monitored real-time PCR ampli-
fication by quantitative analysis of fluorescence
emissions. The reporter dye (FAM) signal was mea-
sured against the internal reference dye (ROX) sig-
nal to normalize for non-PCR-related fluorescence
fluctuations occurring from well to well. The thresh-
old cycle represented the refraction cycle number
at which a positive amplification was measured, and
was set at ten times the standard deviation of the
mean baseline emission calculated for PCR cycles 3
to 15. Analysis of the copy numbers and linear
regression curve was performed using the Sequence
Detector v1.9 software (Applied Biosystems, Foster
City, CA, USA).Figure 1 Ten-fold serial dilutions ranging from 108 to 102
copies of cRNA were tested in duplicate in real-time RT-
PCR. A standard curve graphwas generated by plotting the
CT values on the y-axis and the log of the input amounts on
the x-axis. The slope of this standard curve was3.43 and
the correlation coefficient was 0.997.One-step RT-PCR
To compare the sensitivity of the real-time RT-PCR
with a conventional RT-PCR, a cRNA sample was used
(kindly provided by Professor Dr C. Drosten from the
Bernard Nocht Institute for Tropical Medicine, Ham-
burg, Germany). A 195 bp fragment was amplified by
a one-step RT-PCR using the BNI outer primers (50-
ATGAATTACCAAGTCAATGGTTAC-30 as the sense pri-
mer and 50-CATAACCAGTCGGTACAGCTAC-30 as the
antisense primer). The RT-PCR was carried out on a
Geneamp PCR System 9700 thermal cycler (Applied
Biosystems, Foster City, CA, USA). Each reactioncontained 0.6 mM of sense and antisense primers,
0.4 mM of each dNTP and 2 ml Qiagen OneStep RT-
PCR enzymemix. RT-PCR conditions were as follows:
an initial reverse transcription for 30 min at 50 8C
followed by a PCR activation for 15 min at 95 8C, 45
cycles of amplification (30 sec at 94 8C, 30 seconds
at 50 8C and 1 min at 72 8C) and a final extension
step at 72 8C for 10 min.Results
Absolute viral RNA load quantitation
To determine the amount of genome equivalents/
ml, i.e. the viral RNA load, in cell culture samples,
SARS-CoV cRNA standards were used for the con-
struction of a standard curve (Figure 1). Ten-fold
serial dilutions of cRNA transcripts were used cor-
responding to copy numbers of 102 to 108. Equal
volumes of standard and sample were used for PCR
amplification. SARS-CoV RNA, extracted from the
supernatant of infected Vero E6 cells, which con-
tained a virus titer of 103 CCID50/ml was analysed
and was found to correspond to a viral RNA load of
1.7  1012 RNA copies/ml.
Dynamic range
To investigate the dynamic range of the assay, 10-fold
serial dilutions of the cRNA standard, ranging from 10
to 1012 molecules in the reaction, were tested. The
results were analysed in terms of CT value (the cycle
in which a target sequence is detected). As shown in
Figure 2, the dynamic range of the assay spanned 6
logs ranging from 102 to 108 molecules SARS-CoV per
reaction, corresponding to a range in CT values from
37.45  0.04 to 17.40 0.04.
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Figure 2 The dynamic range of the assay was tested
running 10-fold serial dilutions of the authors’ cRNA stan-
dard ranging from 10 to 1012 molecules in the reaction.
The amplification plot shows delta Rn on the y-axis (Rn:
fluorescence emission intensity of the reporter dye nor-
malized to a passive reference, delta Rn: Rn of an
unreacted sample — Rn value of the reaction) against
the cycle number displayed on the x-axis. The dynamic
range of the assay spans 6 logs ranging from 102 to 108 log
molecules of SARS-CoV RNA per reaction, corresponding to
CT values ranging from 37.45  0.04 for 102 copies to
17.40  0.04 for 108 copies. cRNA standards with a copy
number above or below the dynamic range are not shown.
Table 1 Intra-assay reproducibility of the SARS-CoV
quantitative RT-PCR.
Sample Dilution cRNA
copies
Mean
CT
S.D. CV
(%)
cRNA 1 1  106 1.86  107 18.50 0.07 0.36
1  107 1.86  106 21.66 0.08 0.39
1  108 1.86  105 25.33 0.12 0.48
1  109 1.86  104 28.28 0.12 0.41
1  1010 1.86  103 32.61 0.22 0.66
1  1011 1.86  102 35.31 0.17 0.48
The intra-assay reproducibility was assessed by running dilu-
tions of the cRNA standards ranging from 102 to 107 copies per
reaction. Each of these dilutions was assayed four times per
run. The mean values of the CT, the standard deviations (S.D.)
and the coefficients of variation (CV) were determined.
Table 2 Interassay reproducibility of the SARS-CoV
quantitative RT-PCR.
Sample Dilution cRNA
copies
Mean
CT
S.D. CV
(%)
cRNA 1 1  105 1.86  108 14.80 0.53 3.61
1  106 1.86  107 17.62 0.23 1.32
1  107 1.86  106 21.16 0.18 0.87
1  108 1.86  105 24.22 0.06 0.23
cRNA 2 1  105 1.94  108 15.39 0.36 2.34
1  106 1.94  107 18.89 0.40 2.10
1  107 1.94  106 21.77 0.15 0.71
1  108 1.94  105 25.00 0.09 0.38
cRNA 3 1  105 2.08  108 15.43 0.41 2.69
1  106 2.08  107 18.45 0.27 1.49
1  107 2.08  106 21.57 0.15 0.68
1  108 2.08  105 25.23 0.10 0.38
cRNA 4 1  105 1.85  108 16.22 0.19 1.15
1  106 1.85  107 19.49 0.09 0.46
1  107 1.85  106 23.18 0.08 0.36
1  108 1.85  105 26.95 0.10 0.39
The interassay reproducibility was assessed by running dilu-
tions of the cRNA standards ranging from 105 to 108 copies per
reaction in three assay runs. The mean values of the CT, the
standard deviations (S.D.) and the coefficients of variation
(CV) were determined.Specificity, sensitivity and reproducibility
Experiments were undertaken to assess diagnostic
criteria such as specificity, sensitivity and reprodu-
cibility. Specificity of the primers and probe was
tested using other human coronaviruses OC43 and
229E. No detectable non-specific amplification of
these coronaviruses took place. The sensitivity of
the real-time RT-PCR was investigated by assaying
ten replicates of samples containing 10, 102, 103 or
104 copies of the cRNA standard per reaction. One
hundred copies of the standard cRNA were detected
in all ten replicates. For ten genome equivalents per
reaction, only one out of ten replicates was found to
be positive. The standard deviation of the mean
threshold cycle varied between 0.34 and 0.98 cycles,
resulting incoefficients of variation ranging from0.97
to 2.57%. The intra-assay reproducibility of the SARS-
CoV real-time RT-PCR was assessed by running dilu-
tions of the cRNA standards ranging from 107 to 102
copies per reaction. Each of these dilutions was
assayed four times per run. The mean values of CT,
the standard deviations and the coefficients of var-
iationwere determined. Table 1 shows that the SARS-
CoV cRNA standards can be detected with a coeffi-
cient of variation of less than 0.7%. The interassay
reproducibility of the SARS-CoVreal-timeRT-PCRwas
assessed by running dilutions of the cRNA standards
ranging from 108 to 105 copies per reaction in several
assay runs. The mean values of the CT, the standard
deviations and the coefficients of variation weredetermined (Table 2). The results show that the
SARS-CoV cRNA standard can be detected with a
coefficient of variation of less than 4%.
Comparison of the in-house cRNA standard
with the cRNA standard of Artus Biotech
To validate the in-house cRNA standard, serial ten-
fold dilutions of the in-house standard together with
equivalent dilutions of the commercially available
Artus Biotech standard were assessed in the same
run. Analysing a specific CT value with the two stan-
dard curves resulted in a 100-fold difference in copy
number.
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To demonstrate the feasibility of broad usage of
real-time RT-PCR for both research and clinical
studies, the sensitivity of the real-time RT-PCR
was compared to that of the RT-PCR using the
BNI-outer primer pair. For both assays, ten-fold
dilutions of a sample containing 109 copies per ml
of the BNI cRNA fragment were used. Whereas the
conventional RT-PCR could detect up to 104 copies of
cRNA per reaction, the detection rate of this real-
time RT-PCR assay was 100-fold higher, with a sen-
sitivity up to 102 cRNA copies per reaction.Discussion
Although the initial global outbreak of SARS has
been successfully contained, SARS will remain a
serious concern. The severity of the disease com-
bined with its rapid spread requires a diagnostic test
that can detect the SARS-CoV infection early in the
course of illness. The SARS-CoV can be detected by
conventional and real-time RT-PCR in specimens
obtained from the upper and lower respiratory
tracts, in plasma or serum, and in feces.9,10,13—17
A conventional RT-PCR, although performed as a
one-step reaction in a thermocycler, still requires the
use of PAGE analysis for detection and it takes four to
five hours to complete the test. This real-time RT-
PCR, on the other hand, can generate complete
results within a period of three hours. The speed of
this assay combinedwithaminimumofmanipulations
that need to be performed, make this real-time RT-
PCR an ideal routine protocol for high-throughput
screening of possible SARS-CoV-infected samples.
The assay described here has been shown to be
highly sensitive, with a detection limit of 102 copies
of SARS-CoV per reaction, which is 2 logs more
sensitive than a conventional SARS-CoV RT-PCR.
Furthermore, this assay has a sensitivity that is
similar or even better than that reported for other
existing real-time SARS-CoV assays. This sensitivity
is achieved without the need for a nested step in the
RT-PCR reaction.18
During the first week of illness, the viral load in
the upper respiratory tract specimens is very low,
but will reach a peak around day ten of illness. Since
early diagnosis is important, highly sensitive diag-
nostic methods are necessary to avoid false-nega-
tive results in samples that contain only trace
amounts of the virus in the early phase of the
infection. This study presents a diagnostic real-time
quantitative assay that is sensitive enough to detect
the presence of SARS-CoV even at an early stage of
the illness. The potential for quantitation over awide dynamic range (at least 6 logs) was demon-
strated with low intra- and inter-assay variation.
Furthermore, this method was highly specific for the
SARS-CoV and gave no false-positive results with
HCoV-OC43 and HCoV-229E.
Comparison of the in-house cRNA standard with
the existing cRNA standard of Artus Biotech2,18
showed a 100-fold difference in absolute quantity.
Using the in-house standard, this assay can detect
100 copies per reaction, whereas with the Artus
standard, the detection limit of our assay is one
RNA copy per reaction.
Drosten and co-workers were the first to develop
a standard to quantify the SARS-CoV, and this
standard is also used in the commercial ready-
to-use RT-PCR kit (Artus Biotech). Even after
repeating the cRNA construction several times,
the same results were obtained. At the moment
the correct absolute quantities cannot be pre-
dicted. The Artus Biotech standard is currently
the de facto standard, and it is necessary to point
out that there is a possible 100-fold underestima-
tion of the copy numbers. This underestimation of
the viral load can be important for in vitro and in
vivo antiviral testing, where real-time RT-PCR is
used for virus yield assays and time-of-drug-addi-
tion experiments.19,20Acknowledgements
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